DanDrit Biotech USA

DanDrit Biotech USA was a development-stage biopharmaceutical company focused on dendritic cell-based cancer vaccines, with a lead candidate (MCV) in Phase 3 for colorectal cancer. The company operated as a “virtual” organization, outsourcing manufacturing and clinical operations. Encouraging Phase 2 results in colorectal cancer and non-small cell lung cancer led to a Phase 3 trial, but there is no public evidence of completion or approval. The company acquired OncoSynergy and Enochian Biopharma in 2018, shifting its pipeline toward OncoSynergy’s anti-CD29 monoclonal antibody (OS2966), with plans to rebrand as OncoSynergy and relocate operations to San Francisco. No recent updates suggest ongoing activity since these acquisitions.